Appendix Table E90. Baseline characteristics of patients with ischemic heart disease in studies assessing the predictive ability of the PFA-100 System

| **Author, year [ref]****UID****Country****Study Name** | **Total N Enrolled** **Race (% by group)****Male (%)****Age\*** | **Previous CAD (%)****Previous heart failure(%)****Previous TIA/stroke(%)****History of PCI or CABG(%):****Stable angina(%)****Unstable angina(%)****Previous PAD(%)****History of MI(%)****STEMI/non-STEMI(%)** | **Dyslipidemia (%)****Smokers (%)****BP(mmHg diastolic/systolic** **HTN (%)****Diabetes (%)** | **Vitamin K antagonist(%)****Clopidogrel(%)****Aspirin(%)****PPI(%)** | **Stent implantation(%)****Type of stent(%)****Multi-or single vessel(%)**  | **Current indication for clopidogrel treatment** | **Current antiplatelet regimen** | **Co-medications** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Malek, 200717295159PolandNR | 91NR68median ageGroup1 66 (38, 85)Group 2 59 (51, 82)Group 3 54.5 (48, 71) Controls 58 (35, 86) | NRNRNRNRNRNRNR17.6NR | 34.148.4HTN 50.515.4 | NR98.9100NR | NRNRNR | underwent PCI with stent implantation | All patients received a loading dose of 300 mg of aspirin followed by daily regimen of 75 mg and a loading dose of either 300 or 600 mg of clopidogrel followed by 75 mg daily. | NR |
| Breet, 201120179285NetherlandsNR | 1069NR7564±10.6 | NRNRNRNRNRNRNR54.5NR | 80.311.1HTN 76.918.6 | NR10089.427.8 | 100DES 63.5NR | coronary artery disease scheduled for elective PCI with stent | clopidogrel treatment (a maintenance of 75 mg/d therapy for>5 days or a loading dose of 300 mg ≥24 hours before PCI or 600 mg ≥4 hours before PCI) and aspirin (80-100 mg/d ≥10 days). | unless they were receiving long-term anticoagulation with warfarins |
| Foussas, 200717892990GreeceNone  | 612NR81.762±10.8 | NRNRNRCABG 4.723.5NRNR17.7STEMI 36.3 | Hyper 67.351HTN 48.628.7 | NR100100NR | 100BMS 79.8Sirolimus eluting 20.255.5 | PCI with stenting | aspirin (100-325 mg/d) and clopidogrel (300 or 600 mg as loading dose and then 75 mg/d).  | Unfractioned heparin (70 IU/kg) was given at the start of the procedure. |
| Smit, 201020889993NetherlandsON-TIME-2 | 648NR75.862.3 | NRNRCVA 1.7PCI 7.4; CABG 2.515.2NRNR7.8STEMI 100 | 18.844.9HTN 29.6; systolic 132.8 mmHg; diastolic 79.8 mmHg9.9 | NRNRNRNR | NRNRNR | Patients with ACS (STEMI) | Clopidogrel: (600 mg LD + 75 mg MD daily for 1 year);  | acetylsalicylic acid 500 mg IV; unfractionated heparin 5000 IU IV ± tirobiban (25 mg/kg bolus + MD infusion of 0.15 mg/kg/min of tirofiban or placebo) |
| Huczek, 200818301358PolandNR | 125NR66Mean 62 (range 60-63) | 22NRCV event 3NRNRNRNR15NR | 3748HTN 5224 | NRNRNRNR | NRNRNR | Patients undergoing percutaneous coronary intervention (PCI) for ACS | Clopidogrel: 600-mg LD + 75 mg daily MD for of 30 daysAspirin: 300 mg before angiography + 75 mg daily MD | Abciximab - at the discretion of the operator as a 0.25 mg/kg bolus or a 0.125 μg/kg/min 12-hour infusion. |
| Moerenhout, 201020211306Belgium NR | 250 NRNR66.1 | post ACS 30.1NRNRNR72NRNRNRNR | cholesterol 190.2 (mean)27.7HTN 59.922.6 | NRNRNRNR | NRNR56.2 | Patients undergoing percutaneous coronary intervention (PCI) | aspirin 160 mg LD + 450 mg LD of clopidogrel (300-mg clopidogrel 12 hours before PCI and 150 mg the day of PCI)Clopidogrel 75 mg MD x 6 weeks (bare metal stents) to 6 months (drug-eluting stent) | Unfractionated heparin was administered at the beginning of the procedure and titrated to obtain activated clotted time (ACT) levels between 300 and 350 seconds. |
| Siller-Matula, 200919135705AustriaNR | 30NR63±10 | 100NRCVD 7PCI 43NRNR1037NR | hyper 7757HTN 7733 | NR100100NR | NRNRNR | Patients undergoing PCI for coronary artery disease | Patients had been on chronic aspirin (100 mg/day) and clopidogrel (75 mg/day) treatment for three months on average.  | All patients received unfractionated heparin and 250 mg of injectable acetyl-salicylic acid during PCI  |
| Gori,200819132241Italy RECLOSE | 746NR7568±12 | NRNRNRPCI 23; coronary artery surgery 63340NR2526 | hyper 4923HTN 6120 | NRNRNRNR | 100DES 93multi 57 | RECLOSE patients who underwent DES implantation for whom complete AA- and collagen-induced platelet aggregation values were available. | All patients received aspirin (325 mg) and a loading dose of 600 mg of clopidogrel followed by a maintenance dose of 75 mg daily.  | Patients on a maintenance dose of ticlopidine or clopidogrel at the time of admission received a loading dose of clopidogrel (600 mg). |
| Siller-Matula, 201222260716AustriaPEGASUS-PCI | 416NR7664±12 | NRNRNRPCI 47NRNR133118/NR | hyper 76558432 | NR10010076 | 100DES 99NR | patients undergoing PCI | clopidogrel LD 600mg, MD 75mg | NR |
| Chiu 201121925055TaiwanNR | 144NR76.4%64.8 | NRNR6%NR55.6%NRNR18%NR | 50%Active smoker: 32%NRHTN: 69%47% | NRNRNR9% | NRBMS: 54%; DES: 34%3 vessels: 8% | PCI for ACS  | Clopidogrel (300 mg LD + 75 mg/d MD)Aspirin 100 mg/day for 7 days prior to (stable angina) or 300 mg LD + 100 mg/day (ACS patients) | NR |

\* Mean (standard deviation), unless otherwise stated. **Abbreviations:** ACS = acute coronary syndrome; AMI = acute myocardial infarction; BMS=Bare metal stents; BP = blood pressure; CABG = coronary artery bypass grafting; PTCA=percutaneous transluminal coronary angioplasty; CVA=cerebrovascular accident; CVD=cerebrovascular disease; CAD = coronary artery disease; DES=Drug eluting stent; BMS=bare metal stent; HTN = hypertension, IHD: Ischemic heart disease; MI = myocardial infarction; NSTEMI = non-ST-elevation MI; LVEF=left ventricle ejection fraction; PAD = peripheral artery disease; PCI = percutaneous coronary intervention; STEMI = ST-elevation MI; TIA = transient ischemic attack; PPI=proton pump inhibitor; UFH= Unfractionated Heparin; BP=blood pressure; hyper=hypercholesterolemia; LD=loading dose; MD= maintain dose; ASA=aspirin; GP IIb/IIIa inhibitors =Glycoprotein IIb/IIIa inhibitors
Add headings for additional subgroups. Data are means unless otherwise indicated; estimated is noted if reported as an estimate.